Skip to Content
Merck
  • Processing of high-titer prions for mass spectrometry inactivates prion infectivity.

Processing of high-titer prions for mass spectrometry inactivates prion infectivity.

Biochimica et biophysica acta. Proteins and proteomics (2018-10-05)
Roger A Moore, Anne Ward, Brent Race, Suzette A Priola
ABSTRACT

Prions represent a class of universally fatal and transmissible neurodegenerative disorders that affect humans and other mammals. The prion agent contains a pathologically aggregated form of the host prion protein that can transmit infectivity without any bacterial or viral component and is thus difficult to inactivate using disinfection protocols designed for infectious microorganisms. Methods for prion inactivation include treatment with acids, bases, detergents, bleach, prolonged autoclaving and incineration. During these procedures, the sample is often either destroyed or damaged such that further analysis for research purposes is compromised. In this study we show that a straightforward denaturation and in-gel protease digestion protocol used to prepare prion-infected samples for mass spectroscopy leads to the loss of at least 7 logs of prion infectivity, yielding a final product that fails to transmit prion disease in vivo. We further show that the resultant sample remains suitable for mass spectrometry-based protein identifications. Thus, the procedure described can be used to prepare prion-infected samples for mass spectrometry analysis with greatly reduced biosafety concerns.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
1,1,1-Trifluoro-5,5-dimethyl-2,4-hexanedione, 98%
Sigma-Aldrich
Phosphotungstic acid hydrate, 99.995% trace metals basis (Purity excludes up to 300 ppm Si)